• Dedy C. Haryono Department of Surgery, Sebelas Maret University, Surakarta, Indonesia
  • Joko Purnomo Department of Surgery, Dr. Moewardi General Hospital, Surakarta, Indonesia
  • Richard Philo Sebelas Maret University, Surakarta, Indonesia



Ameloblastoma, Adamantinoma, Oral cavity


Ameloblastoma is a noncancerous tumor that originates from epithelial tissue in the oral cavity. It is regarded as one of the most aggressive odontogenic tumors (OT) in several nations throughout the world. If left untreated, they can grow to be quite big, causing facial disfigurement and functional issues. The treatment of ameloblastoma depends on the size, location, and histological subtype of the tumor. Surgical resection is the mainstay of treatment, and various techniques have been developed to minimize morbidity and recurrence.


Effiom OA, Ogundana OM, Akinshipo AO, Akintoye SO. Ameloblastoma: current etiopathological concepts and management. Oral Dis. 2018;24(3):307-16.

Cadavid AMH, Araujo JP, Coutinho-Camillo CM, Bologna S, Junior CAL, Lourenço SV. Ameloblastomas: current aspects of the new WHO classification in an analysis of 136 cases. Surg Exp Pathol. 2019;2(1):4-9.

Maia EC, Sandrini FAL. Management techniques of ameloblastoma: a literature review. Rev Gaúcha Odontol. 2017;65(1):62-9.

Ranchod S, Titinchi F, Behardien N, Morkel J. Ameloblastoma of the mandible: Analysis of radiographic and histopathological features. J Oral Med Oral Surg. 2021;27(1):1-8.

Pandiar D, Anand R, Kamboj M, Narwal A, Shameena PM, Devi A. Metastasizing Ameloblastoma: A 10 Year Clinicopathological Review with an Insight Into Pathogenesis. Head Neck Pathol. 2021;15(3):967-74.

Masthan KMK, Anitha N, Krupaa J, Manikkam S. Ameloblastoma. J Pharm Bioallied Sci. 2015;7(4):S167-70.

Nivia M, Padmakumar SK, Mohan U, Andrews A. Pathogenesis of Ameloblastoma -A Review Pathogenesis of Ameloblastoma-A Review. 2020.

Ragunathan YT, Kumar SK, Janardhanam D, Ravi A, Santhanam V, Ramdas MN. Prevalence and Epidemiological Profile of Ameloblastoma in India: A Systematic Review and Meta-Analyses. Asian Pacific J Cancer Prev. 2022;23(11):3601-10.

Chae MP, Smoll NR, Hunter-Smith DJ, Rozen WM. Establishing the natural history and growth rate of ameloblastoma with implications for management: Systematic review and meta-analysis. PLoS One. 2015;10(2).

Narayan Biswal B, Narayan Das S, Kumar Das B, Rath R. Alteration of cellular metabolism in cancer cells and its therapeutic. J Oral Maxillofac Pathol. 2017;21(3):244-51.

Filizzola AI, Bartholomeu-Dos-Santos TCR, Pires FR. Ameloblastomas: Clinicopathological features from 70 cases diagnosed in a single Oral Pathology service in an 8-year period. Med Oral Patol Oral y Cir Bucal. 2014;19(6):e556-61.

Bwambale P, Yahaya JJ, Owor G, Wabinga H. Histopathological patterns and biological characteristics of ameloblastoma: A retrospective cross-sectional study. J Taibah Univ Med Sci. 2022;17(1):96-104.

Speight PM, Takata T. New tumour entities in the 4th edition of the World Health Organization Classification of Head and Neck tumours: odontogenic and maxillofacial bone tumours. Virchows Arch. 2018;472(3):331-9.

Ghai S. Ameloblastoma: An Updated Narrative Review of an Enigmatic Tumor. Cureus. 2022;14(8):1-9.

Wright JM, Vered M. Update from the 4th Edition of the World Health Organization Classification of Head and Neck Tumours: Odontogenic and Maxillofacial Bone Tumors. Head Neck Pathol. 2017;11(1):68-77.

Yang R, Liu Z, Gokavarapu S, Peng C, Cao W, Ji T. Recurrence and cancerization of ameloblastoma: Multivariate analysis of 87 recurrent craniofacial ameloblastoma to assess risk factors associated with early recurrence and secondary ameloblastic carcinoma. Chinese J Cancer Res. 2017;29(3):189-95.

Sweeney RT, Andrew C McClary, Myers BR, Biscocho J, Neahring L, Kwei KA et al. Identification of recurrent SMO and BRAF mutations in ameloblastomas. Nat Genet. 2014;46(7):722-5.

Diniz MG, Gomes CC, Guimarães BVA, Castro WH, Lacerda JCT, Cardoso SV et al. Assessment of BRAFV600E and SMOF412E mutations in epithelial odontogenic tumours. Tumor Biol. 2015;36(7):5649-53.

Shi HA, Ng CWB, Kwa CT, Sim QXC. Ameloblastoma: A succinct review of the classification, genetic understanding and novel molecular targeted therapies. Surgeon. 2021;19(4):238-43.

Brunner P, Bihl M, Jundt G, Baumhoer D, Hoeller S. BRAF p.V600E mutations are not unique to ameloblastoma and are shared by other odontogenic tumors with ameloblastic morphology. Oral Oncol. 2015;51(10):e77-8.

Brown NA, Betz BL. Ameloblastoma: A Review of Recent Molecular Pathogenetic Discoveries. Biomark Cancer. 2015;7s2:BIC.S29329.

Kreppel M, Zöller J. Ameloblastoma-Clinical, radiological, and therapeutic findings. Oral Dis. 2018;24(1-2):63-6.

Wright JM, Soluk-Tekkeşin M. Odontogenic Tumors: Where are we in 2017? J Istambul Univ Fac od Dent. 2017;51:10-30.

Kallianpur S, Jadwani S, Misra B, Sudheendra US. Ameloblastic carcinoma of the mandible: Report of a case and review. J Oral Maxillofac Pathol. 2014;18(5):96-102.

Slusarenko da Silva Y, Tartaroti NA, Sendyk DI, Deboni MCZ, Naclério-Homem M da G. Is conservative surgery a better choice for the solid/multicystic ameloblastoma than radical surgery regarding recurrence? A systematic review. Oral Maxillofac Surg. 2018;22(4):349-56.






Review Articles